Premium
Quercetin supplementation does not enhance antibody responses to influenza vaccination
Author(s) -
Henson Dru A,
Kohut Marian L,
Nieman David C,
Heinz Serena A,
Yin Fuxia
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.723.5
Subject(s) - medicine , vaccination , seroconversion , placebo , hemagglutination assay , immunology , titer , antibody titer , adjuvant , antibody , alternative medicine , pathology
Although vaccination is an effective strategy for prevention of influenza, its efficacy is limited, especially in older adults. A search for novel adjuvant strategies to increase vaccine efficacy is ongoing. Quercetin (Q), a plant flavonoid is attributed with numerous health benefits due to its anti‐inflammatory and immunomodulating properties. The effects of 8‐wks Q supplementation on the antibody (AB) response to influenza immunization was studied in 82 subjects (ages 41–83 y) randomized to Q‐500 (500 mg/d Q, N=32), Q‐1000 (1000 mg/d Q, N=25) or placebo (N=25) groups. Subjects ingested supplements for 4‐wks, provided blood samples, were vaccinated with the 2008–09 trivalent influenza Afluria® vaccine containing A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2) and B/Florida/4/2006, and provided blood samples after 4 additional wks of supplementation. Q supplementation at two doses compared to placebo increased plasma Q (P<0.001), however no group differences were found for hemagglutination inhibition AB titers or seroconversion rates for any viral strain. Compared to placebo, Q‐1000 attenuated post‐vaccination increases in IgG for H1N1 and B (but not H3N2) and significantly reduced post‐vaccination IgG to all viruses combined by 83% (P=0.025). In conclusion, Q supplementation does not improve the AB response to influenza vaccination. Supported by grants from Coca‐Cola and Quercegen Pharma.